Commercialisation director joins Edinburgh BioQuarter

Life sciences entrepreneur Michael Capaldi joins Scotland\'s flagship project

Commercialisation director joins Edinburgh BioQuarter
Michael Capaldi, scientist and life sciences entrepreneur, has been named as director of commercialisation for the Edinburgh BioQuarter – Scotland’s flagship project for the life sciences sector.

Capaldi will lead a team of up to 15 people to progress a £12m commercialisation project that will bridge the gap between industry and research.

Capaldi has more than 26 years’ experience in the pharmaceutical and life sciences industries within the UK, Europe and the US.

You may also like

Research & Development

University of Edinburgh to collaborate with Galapagos on cancer therapies

Two-year partnership with plans to extend
Manufacturing
The 7 most common process development mistakes

The 7 most common process development mistakes

At laboratory scale, processes may appear predictable, repeatable, and well understood. However this perceived level of control can be misleading
Manufacturing
What are injectable hydrogel microspheres?

What are injectable hydrogel microspheres?

The demand for longer-lasting therapies is accelerating innovation in injectable drug delivery, driven by the need to maintain stable therapeutic levels while minimising repeated administration
Regulatory
Pheno Therapeutics gains FDA IND clearance for first-in-class GPR17 antagonist PTD802 in MS

Pheno Therapeutics gains FDA IND clearance for first-in-class GPR17 antagonist PTD802 in MS

The clearance enables a first-in-human trial of the UCB-licensed remyelination candidate, marking the first GPR17 programme to reach clinical development for multiple sclerosis and related demyelinating diseases
Research & Development
Promega UK Launches Lumit Cell Proliferation Assay (Human Ki-67) for rapid, wash-free detection of a key proliferation marker

Promega UK Launches Lumit Cell Proliferation Assay (Human Ki-67) for rapid, wash-free detection of a key proliferation marker

New homogeneous, plate-based assay enables researchers to track hKi-67 in a simple add-and-read format, delivering robust and reproducible results in less time
Research & Development
BioArctic and Lilly sign $30m collaboration combining BrainTransporter with Lilly neurodegeneration asset

BioArctic and Lilly sign $30m collaboration combining BrainTransporter with Lilly neurodegeneration asset

The deal, worth up to $800m including milestones, marks BioArctic's fourth BrainTransporter partnership — joining existing collaborations with Eisai, Bristol Myers Squibb and Novartis to advance brain-targeted biologics delivery
You need to be a subscriber to read this article.
Click here to find out more.
Research & Development
Mabion and Oddifact to explore orphan drug potential of MabionCD20 through new collaboration

Mabion and Oddifact to explore orphan drug potential of MabionCD20 through new collaboration

Mabion has signed a letter of intent with Oddifact to reposition its Phase III-stage CD20 monoclonal antibody candidate for rare disease indications, leveraging AI-driven orphan drug identification and existing manufacturing expertise
Subscribe now